A detailed history of Reap Financial Group, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Reap Financial Group, LLC holds 200 shares of ALLO stock, worth $390. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Previous 200 -0.0%
Holding current value
$390
Previous $560,000 23.93%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Feb 27, 2025

BUY
$2.92 - $5.63 $584 - $1,126
200 New
200 $894,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $280M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Reap Financial Group, LLC Portfolio

Follow Reap Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reap Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reap Financial Group, LLC with notifications on news.